Diabetic peripheral neuropathy is the most common complication of diabetes and a source of considerable morbidity. Numerous molecular pathways are linked to neuropathic progression, but it is unclear whether these pathways are altered throughout the course of disease. Moreover, the methods by which these molecular pathways are analyzed can produce significantly different results; as such it is often unclear whether previously published pathways are viable targets for novel therapeutic approaches. In the current study we examine changes in gene expression patterns in the sciatic nerve (SCN) and dorsal root ganglia (DRG) of db/db diabetic mice at 8, 16, and 24 weeks of age using microarray analysis. Following the collection and verification of gene expression data, we utilized both self-organizing map (SOM) analysis and differentially expressed gene (DEG) analysis to detect pathways that were altered at all time points. Though there was some variability between SOM and DEG analyses, we consistently detected altered immune pathways in both the SCN and DRG over the course of disease. To support these results, we further used multiplex analysis to assess protein changes in the SCN of diabetic mice; we found that multiple immune molecules were upregulated at both early and later stages of disease. In particular, we found that matrix metalloproteinase-12 was highly upregulated in microarray and multiplex data sets suggesting it may play a role in disease progression.
Introduction
Type 2 diabetes (T2D) is a metabolic disorder which arises primarily from obesity and is characterized by hyperglycemia, hyperlipidemia, and impaired insulin signaling. As T2D progresses, these factors lead to microvascular complications which significantly increase both the morbidity and the mortality of afflicted patients (Kim et al., 2011; Edwards et al., 2008) . In particular, diabetic peripheral neuropathy (DPN) is one of the most common diabetic complications, with 50% of T2D patients developing DPN (Callaghan et al., 2015) . DPN is characterized by progressive loss of sensation in the limbs, pain, and allodynia. It also increases infection risk and the rate of foot ulcers that can lead to amputation (Callaghan et al., 2015) .
Despite the prevalence of T2D and the morbidity associated with DPN, the mechanisms of neurodegeneration are poorly understood. Numerous pathways, including inflammation (Pop-Busui et al., 2016) , reactive oxygen species (ROS) formation (Hur et al., 2010; Hinder et al., 2013) , mitochondrial dysfunction , and endoplasmic reticulum stress (O'Brien et al., 2014) are implicated and may play a role in disease progression. To elucidate potential mechanisms, previous studies have utilized either microarray or RNA-Seq analyses to identify genes which are up-or downregulated in the peripheral nervous system during DPN Wiggin et al., 2008; Pande et al., 2011; Hur et al., 2016; Hur et al., 2011; Hinder et al., 2017a) . However, these studies have focused on specific time frames and do not examine changes over the course of disease; pathways that are upregulated early or late in disease may not necessarily play an important role over the entirety of the disease course.
Using microarrays as a transcriptomic platform, we identified DPNassociated pathways in the sciatic nerve (SCN) and dorsal root ganglia (DRG) at 8, 16, and 24 weeks of age in the well characterized db/db mouse model of T2D and DPN. Previously published 16 and 24 week transcriptomic datasets Pande et al., 2011) were preprocessed with new datasets using a unified analysis pipeline. Two forms of data analyses were then used in parallel to identify altered molecular pathways in DPN. First, using Self-Organizing Map (SOM) analysis, pathways of interest were organized into distinct clusters which followed similar kinetic patterns over the course of disease. Next, Differential Expression Analysis was used to identify up-and downregulated differentially expressed genes (DEGs) at all three time points. By comparing both sets of analyses, we found that pathways associated with inflammation and immune regulation were altered at all time points in both the SCN and the DRG. To validate these data, multiplex analysis was used to assess protein changes in the SCN during early (8 week) and late (24 week) stages of DPN. Several pro-and anti-inflammatory markers, including interferon (IFN)-γ and interleukin (IL)-10, were upregulated over the course of disease. Also, consistent with our previous observations O'Brien et al., 2015) , we found that matrix metalloproteinase-12 (MMP-12) was highly upregulated in DPN. Together, these data suggest that the immune system plays a key role during DPN and that aspects of the immune system may represent a viable therapeutic target.
Methods

Animals
Three cohorts of C57BLKS (BKS·Cg-m+/+Lepr db /J; stock number 000642, Jackson Laboratory, Bar Harbor, ME) db/db mice, a wellcharacterized murine model of T2D, were used for the study. Control (db/+) and diabetic (db/db) mice were fed a standard diet (5LOD, 13.4% kcal fat for 8/24 week; or AIN76A, 11.5% kcal fat for 16 week; Research Diets, New Brunswick, NJ). Mice were cared for in a pathogen-free environment by the University of Michigan Unit for Laboratory Animal Medicine. Mice were, euthanized at 8, 16 or 24 weeks of age using a lethal injection of pentobarbital (Vortech, Dearborn, MI). Animal protocols were approved by the University of Michigan University Committee on Use and Care of Animals.
Metabolic and neuropathy phenotyping
Control db/+ and db/db mice were phenotyped for body weight, fasting blood glucose (FBG), and glycated hemoglobin (GHb) levels (n = 5-6 for each group per time point). FBG levels were measured with an AlphaTrak Glucometer (Abbott Laboratories, Abbott Park, IL) for 8 and 16 week mice and a standard Glucometer (OneTouch; LifeScan Inc., Milpitas, CA) for 24 week mice. GHb levels were determined using a Glyco-Tek Affinity column (Helena Laboratories, Beaumont, TX) at the Michigan Diabetes Research and Training Center Chemistry Core. Peripheral nerve function was assessed at 8, 16, and 24 week according to Diabetic Complications Consortium guidelines (https://www.diacomp.org/shared/protocols.aspx). Motor (sciatic) and sensory (sural) nerve conduction velocities (NCVs), hind-paw withdrawal latency from a thermal stimulus, and intraepidermal nerve fiber density were measured for large and small fiber nerve function, and small fiber loss using our previously published protocols (Oh et al., 2010; Cheng et al., 2009; Cheng et al., 2012; Hinder et al., 2017b) . Data from 16 week and 24 week cohorts are previously published Pande et al., 2011) .
Microarray data analyses
Lumbar DRG were harvested, and nerve roots removed under a dissecting microscope. A 15 mm segment of SCN was harvested immediately proximal to the sural/tibial/peroneal trifurcation, and adherent fat and connective tissue removed under a dissecting microscope. Total RNA was collected from SCN and DRG at 8 week (db/+, n = 5; db/db, n = 6), 16 week (db/+, n = 6; db/db, n = 6), and 24 week (db/+, n = 6; db/db, n = 6) using the silica gel-based isolation protocol RNeasy Mini Kit (QIAGEN, Valencia, CA) at each time point. RNA quality was measured using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Samples meeting RNA quality criteria were analyzed by microarray as previously described . In brief, total RNA (75 ng) was amplified and biotin-labeled using the Ovation Biotin-RNA Amplification System (NuGEN Technologies Inc., San Carlos, CA) per the manufacturer's protocol; amplification and hybridization were performed by the University of Michigan DNA Sequencing Core using the Affymetrix GeneChip® Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA). These studies include previously published transcriptomics datasets (16 week SCN and DRG ; 24 week SCN ).
Quality control
The quality of the microarray CEL files were assessed using the affyAnalysisQC R package (http://arrayanalysis.org) with Bioconductor (www.bioconductor.org). The Robust Multi-array Average method with the BrainArray Custom Chip Definition File version 19 (Dai et al., 2005) was applied to normalize each group of microarray data using GenePattern (http://genepattern.broadinstitute.org/gp/).
Self-organizing map analysis
Patterns of gene expression were identified during DPN progression in SCN and DRG in an unbiased manner using SOM analysis. To compare the gene expression changes across the groups, fold-change (FC) values of all genes at 8, 16, and 24 week for each tissue were calculated. Due to biological and technical variation resulting from different harvest time points and microarray batches, a log 2 -transformed foldchange ratio between db/+ and db/db was used for SOM input data. To enhance the visualization of SOM algorithms, Melikerion (Version 1.2.1) software (http://www.finndiane.fi/software/melikerion/) was used with a 7 × 7 grid structure (Makinen et al., 2008) . Genes having a similar FC pattern across the groups were gathered together in cells called "modules". Functional enrichment analysis using DAVID (http:// david.abcc.ncifcrf.gov) based on Gene Ontology with a BenjaminiHochberg (BH) corrected p-value (< 0.05) identified the enriched functions in each module (Huang et al., 2009 ). Pathway enrichment analysis was then performed to identify significantly enriched canonical pathways with a BH corrected p-value (< 0.05) for the clusters of interest using Ingenuity Pathway Analysis software (www.qiagen.com/ ingenuity).
Differential expression analysis
Conventional differential analysis was performed by pairwise comparisons between groups (db/+ vs. db/db) for each group in SCN and DRG. DEGs were determined using the Significance Analysis of Microarrays tool (Tusher et al., 2001 ) with an estimated false discovery rate of < 0.05 on the basis of 1000 permutations. Next, DEG sets were identified at each time point to identify unique and common DEG sets between time points. To functionally characterize DEG sets common between all three time points, pathway enrichment analysis was then performed to identify significantly enriched canonical pathways with a BH corrected p-value (< 0.05) using Ingenuity Pathway Analysis software (www.qiagen.com/ingenuity).
Multiplex analysis
Cytokine levels were analyzed in SCN from an additional cohort of 8-(n = 6 per group) and 24-week (n = 6 per group) db/+ and db/db mice as previously described (O'Brien et al., 2015) . Briefly, SCN samples were homogenized and cytokine concentrations in the lysate were analyzed using MILLIPLEX xMAP magnetic bead technology (Millipore, Billerica, MA) with an MMP-12 (MMMP3MAG-79K) and custom cytokine/chemokine panel (MCYTOMAG-70K). Multiplex assays were run on a Bio-Plex200 multiplex array system with Bio-Plex Manager™ 6.0 software (BioRad, Hercules, CA) according to the manufacturer's instructions. Protein levels of 17 immune markers were determined: eotaxin, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-13, IP-10, KC, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and MMP-12.
Statistical analysis
F-tests were used to determine whether data sets were normally distributed. For phenotypic measurements, which were normally distributed, statistically significant differences were determined using a two-tailed t-test. For Multiplex assays, which were non-normally distributed, comparisons were performed using the non-parametric MannWhitney U test. All tests were performed using Prism 6 software (GraphPad Software, La Jolla, CA).
Results
Project workflow
We attempted to identify key pathways in DPN by assessing gene expression changes at multiple time points in the db/db mouse model of T2D (Fig. 1) . First, db/+ control mice and db/db diabetic mice were phenotyped at 8, 16, and 24 week to verify metabolic changes and the development of DPN. Next, SCN and DRG were harvested at 8, 16, and 24 week. Gene expression was assessed using microarray technology, and parallel analyses using SOM and DEG identified pathways of interest. Results were cross-referenced and changes in the immune system were validated using multiplex protein analysis. Fig. 1 . Study workflow. Control db/+ and diabetic db/db mice underwent phenotypic assessment at 8, 16, and 24 weeks of age. Mice were euthanized at each time point and the sciatic nerve and dorsal root ganglia collected; total RNA was collected from each tissue type, gene expression assessed using microarray, processed, and checked for quality. Processed data were then analyzed in parallel using SOM or DEG analysis. Functional enrichment and canonical molecular pathways associated with altered gene expression were identified using DAVID and IPA. Finally, multiplex was used to assess protein expression levels and validate pathways detected using SOM and DEG analyses.
Metabolic
Metabolic and neuropathy phenotyping
To verify that db/db mice develop long-term metabolic changes as well as DPN, body weights, and hyperglycemia for db/+ and db/db mice at 8, 16, and 24 week of age were measured ( Supplementary  Fig. 1 ). For all time points, db/db mice were significantly heavier than db/+ mice ( Supplementary Fig. 1A ). FBG and GHb were significantly increased in db/db mice as well, particularly at later time points ( Supplementary Fig. 1B, 1C) .
In parallel, we measured four standard metrics of neuropathy at 8, 16, and 24 weeks of age: sciatic motor NCV ( Supplementary Fig. 1D ), sural NCV ( Supplementary Fig. 1E ), hind-paw withdrawal latency ( Supplementary Fig. 1F ), and intraepidermal nerve fiber density (IENFD) (Supplementary Fig. 1G ). IENFD was significantly reduced in 16 and 24 week db/db mice compared to controls, while sural and sciatic NCVs were significantly reduced at all time points. Finally, hindpaw withdrawal latency was significantly increased at 16 and 24 week of age. Together, these data indicate that db/db mice display metabolic changes over the course of their life and develop DPN that is particularly pronounced by 16 and 24 week of age.
Self-organizing map analysis
We next attempted to identify mechanistic pathways that are altered at all time points of DPN that can therefore serve as viable therapeutic targets. We used microarray technology to assess gene expression levels in the SCN and DRG of db/+ and db/db mice. First, to verify appropriate tissue dissections, we confirmed that expression levels of the skeletal muscle-specific transcript, myogenic differentiation 1 (Myod1) was negligible in DRG and SCN tissue, while positive controls were present in DRG (advillin, Avil) and SCN (peripheral myelin protein 22, Pmp22) (Supplementary Table 1) . Using SOM analysis, we examined changes in gene expression patterns across the 8, 16, and 24 week time points. For each tissue, the 17,856 genes detected were organized into a SOM consisting of 7 × 7 modules ( Fig. 2A, B) . Each module represents a unique pattern of gene expression across the three time points. To visualize changes in gene expression in db/db mice compared to db/+ mice, modules with large expression changes are represented by red, whereas genes with smaller expression changes are blue. Each module was subjected to DAVID analysis to generate heat-maps for both SCN ( Supplementary Fig. 2 ) and DRG ( Supplementary Fig. 3 ). Adjacent modules with similar patterns and large changes in gene expression were grouped together into clusters. These clusters were then analyzed using IPA to identify canonical molecular pathways that were significantly altered in SCN and DRG (Tables 1-3) .
Within the SCN, IPA analysis of Cluster 1 detected changes in molecular pathways related to axonal loss, axonal and neuronal differentiation, neuronal projection development, and neurological system processing. These mechanisms were highly upregulated at 8 week but downregulated by 24 week (Fig. 2B ). Despite this, none of the canonical pathways identified using IPA reached the level of statistical significance at all three time points (data not shown). In contrast, pathways in Cluster 2 were upregulated at 8, 16, and 24 week. Pathways that were significantly altered at all three time points were primarily associated with immune function including immune cell signaling, trafficking, and activity (Table 1) .
Pathway changes were also detected in the DRG (Fig. 2C) . Cluster 1 contained pathways that were downregulated at all time points, particularly 8 and 24 week (Fig. 2D) . Using IPA to detect enriched canonical pathways, we found that these downregulated pathways were related primarily to immune function, extracellular matrix function, and molecular signaling (Table 2) . Pathways in Cluster 2 of the DRG paralleled those in the SCN: gene expression was upregulated at all time points (Fig. 3D ). Within Cluster 2 canonical pathways we observed upregulated genes primarily associated with immune functions (Table 3 ). In addition, several other enriched pathways, notably those related to the complement system and ROS production, play a central role in the immune response.
Differential expression analysis
Results of microarray analyses can be highly variable, as different analyses can often yield very different results (Rapaport et al., 2013; Soneson and Delorenzi, 2013) . To complement our SOM analysis and strengthen these results, we also analyzed gene expression in SCN and DRG using Differentially Expressed Gene (DEG) analysis at 8, 16, and A B
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(1,1) Fig. 2. Self-Organizing Map analysis. SOM analysis was used to identify coherent patterns of gene expression in sciatic nerve (A) and dorsal root ganglia (C) at 8, 16, and 24 weeks of age. Genes with similar expression patterns were organized into modules; those with small expression changes relative to control mice organize into the center of the map (blue hexagons) while those with large changes organize in the corners (red hexagons). Modules with similar kinetic patterns were organized into clusters. Clusters from each tissue type were examined at 8, 16, and 24 weeks to determine how gene expression changed over the course of disease. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 24 week and interpreted the resulting data using multiple techniques (Fig. 1) . We began by generating pairwise comparisons (db/+ vs. db/ db) for each gene in the SCN and DRG at each time point (Fig. 3A, B) . For each comparison, if the difference between genes in db/+ vs. db/db mice are significantly different then they are considered to be differentially expressed. Thus, these genes are considered to be DEGs regardless of whether they are over-or under-expressed in db/db mice compared to controls. Using DEG analysis, we found that at 8 week, 3241 (SCN) and 3438 (DRG) genes were significantly up-or downregulated; at 16 week, 1756 (SCN) and 2115 (DRG) DEGs were identified, while 3662 (SCN) and 1835 (DRG) DEGs were identified at 24 week. Next, to determine which genes are differentially regulated throughout the course of disease, we compared the DEGs from all three time points in the SCN and in the DRG. Of the 8659 DEGs detected in the SCN, we found that 225 genes were differentially expressed at all three time points (Fig. 3C) . Similarly, of the 7388 DEGs in the DRG we identified 361 genes differentially expressed at 8, 16, and 24 week (Fig. 3D ).
These two pools of genes (225 SCN, 361 DRG) were then analyzed using two separate methods to identify potential mechanisms of disease. First, a simple analysis was performed whereby the top 20 most upregulated and top 20 most downregulated genes were ranked for each tissue. In the SCN upregulated genes included those associated with bioenergetics but also with numerous aspects of the immune system, particularly Mmp12 (Supplementary Table 2 ). Downregulated genes included structural genes as well as several genes associated with immunity (Supplementary Table 3) . Similarly, genes upregulated in the DRG were associated with immune function (Il1r2, Timp4) (Supplementary Table 4) , while downregulated genes were associated with compromised lipid homeostasis (Them5, Pmp2) (Supplementary Table 5 ).
Next, IPA was used on both the SCN and DRG data sets to identify altered biological pathways within the DEGs at all three time points. Unsurprisingly, within the SCN the most highly enriched pathways were associated with atherosclerosis signaling and obesity-related leptin signaling. Also highly upregulated, however, were pathways associated with immune cell maturation, cytokine signaling, antigen presentation, the complement system, ROS, and graft-vs-host disease (Table 4) . IPA analysis of DRG detected enriched pathways primarily related to biosynthesis (Table 5) . However, the top enriched pathway was linked to the behavior of macrophages in rheumatoid arthritis, and several other immune-related pathways were detected including the fibrotic response, ROS activity, and pathogen-associated molecular pattern receptors. Together, these data support the SOM analysis and suggest that the immune system plays a role in DPN.
We cannot exclude the possibility that genetic disruption of leptin Fig. 3 . Differential Expression Analysis. Gene expression from sciatic nerve (A, C) and dorsal root ganglia (B, D) were analyzed using differential expression analysis. (A, B) Significantly up-or down-regulated genes were detected in db/db mice (compared to db/+ control mice) at 8, 16, 24 weeks of age in both tissue types. (C, D) The number of genes that were significantly up-or down-regulated were compared between time points to identify genes that were altered over the entire course of DPN (white numbers). signaling contributes to DPN progression in the db/db mouse. A comparison of Lep/Lepr gene regulation between the db/db model and nongenetic models of DPN could address this issue.
Multiplex chemokine/cytokine analysis
To confirm that changes in the immune system occur in DPN, we used multiplex analysis to assess chemokine/cytokine protein levels in the SCN during early (8 week) and late (24 week) time points in both db/+ and db/db mice (Table 6 ). Consistent with our SOM and DEG analyses, we observed significant increases in immune markers, such as IL-10, eotaxin (also known as CCL11) at 24 week, IFN-γ, and MMP-12. We next compared these increases to those observed in our microarray analysis (Fig. 4) . While we observed negligible increases or minor decreases in eotaxin, Ifng, and early Il10 gene expression in our micro array data sets, we observed increased gene expression of Il10 at 24 week and increased Mmp12 expression during early and late DPN. These data further support a central role for the immune system in DPN and highlight several potential therapeutic targets.
Discussion
Previous studies have examined molecular pathways associated with DPN progression; however, they have done so by examining gene expression during specific intervals. As molecular pathways involved in DPN may be altered during specific time windows, it is therefore important to examine pathway alterations across the entire disease course. Importantly, pathways commonly regulated at all stages of DPN would represent promising therapeutic targets, and the identification of these pathways thus formed the basis of the current study. In order to identify potential pathways of interest, we compared gene expression in the SCN and DRG of control db/+ and diabetic db/db mice at 8, 16, and 24 weeks of age using microarray. Data were then analyzed using two separate methods -SOM and DEG -and functional enrichment and canonical molecular pathways were identified using DAVID and IPA. Finally, gene expression data were verified using multiplex analysis to assess immune protein levels in the SCN at early (8 week) and late (24 week) stages of disease.
Metabolic and neuropathic phenotyping of control and diabetic L.M. Hinder et al. Experimental Neurology 305 (2018) 33-43 mice demonstrated significant changes in db/db mice compared to controls at every time point. SOM and DEG analysis found increases in immune-associated pathways in both SCN and DRG across all time points. Subsequent protein quantification in SCN using multiplex analysis further found that IFN-γ, IL-10, and MMP-12 are all upregulated during early and late DPN. Together, these data indicate that the immune system is involved at all stages of DPN. Inflammation is linked to obesity, with markers of inflammation upregulated in mouse models of disease as well as in diabetic patients (O'Brien et al., 2015; Lumeng et al., 2007; Lumeng, 2013; Lumeng et al., 2008; O'Rourke and Lumeng, 2013; Singer and Lumeng, 2017; O'Brien et al., 2017a; Cooper et al., 2017) . Moreover, altering specific immune pathways can ameliorate insulin resistance and obesity in T2D (Xu et al., 2012; Zlotnikov-Klionsky et al., 2015; Osborn et al., 2012; Li et al., 2015; Kleinridders et al., 2009) . The role of immunity in diabetic neuropathy in Type 1 Diabetes Mellitus (T1D) has been established as well (Urabe et al., 2016; Urabe et al., 2015; Zochodne and Ho, 1994) , and involvement of the immune system likely extends to DPN in T2D (Pop-Busui et al., 2016; O'Brien et al., 2015; O'Brien et al., 2017a; Zhou and Zhou, 2014; O'Brien et al., 2017b) . T2D patients with DPN have higher levels of circulating inflammatory cytokines than both control patients and diabetic patients lacking neuropathy (Doupis et al., 2009 ); immune cells such as monocytes -which are already more activated in patients with T2D (Giulietti et al., 2004; Giulietti et al., 2007; Omoto et al., 2002 ) -traffic at increased rates to non-adipose tissue (Obstfeld et al., 2010) . However, the exact role of the immune system in DPN is not clear, as the immune system can protect or damage sensitive neuronal tissue depending on the local immune environment (Davis et al., 2013) . Moreover, in the case of chronic inflammation, increased levels of both pro-and anti-inflammatory signals are often present simultaneously, further complicating our understanding of potential mechanisms (Murdock et al., 2011) .
The current study suggests a similar complex role for the immune system in DPN. Our SOM analysis -as well as increased eotaxin protein levels in SCN during late disease -suggests that immune cell recruitment is central to pathology. This is consistent with previous reports demonstrating that obesity results in increased levels of immune chemoattractants (Li et al., 2015; Guan et al., 2011) and that immune trafficking promotes diabetic complications including neuropathy (O'Brien et al., 2015) and nephropathy (Chow et al., 2005) . Alternatively, the immune system may be playing -or attempting to play -a role in neuronal repair during DPN. SOM analysis and multiplex revealed that IL-10 production and associated pathways are upregulated in db/db mice during early and later stages of disease, and eotaxin -a Th2-associated chemokine -is upregulated at 24 week as well. Both IL-10 and the Th2 response are associated with protection and tissue repair. Similarly, macrophages and neutrophils are centrally involved in neuronal repair (London et al., 2013; Butterfield et al., 2006; Kurimoto et al., 2013) and myelin remodeling (Rawji et al., 2016) (Martini et al., 2008) .
Involvement of macrophages in DPN is supported by previous studies as well our pathway analyses showing increased phagosome formation. Inflammation in obesity is based on the innate immune system (Subramanian et al., 2015) , with monocyte-derived macrophages as the primary drivers of adipose tissue inflammation (Lumeng et al., 2007) . Previous studies have found that monocytes from T2D patients have a pro-inflammatory profile (Giulietti et al., 2004; Giulietti et al., 2007; Omoto et al., 2002; Yang et al., 2012) , that high glucose levels induce monocyte production of inflammatory signals (Shanmugam et al., 2003) , that depletion of macrophages can ameliorate neuropathic pain (Willemen et al., 2014) , and that macrophages are responsible for clearing debris from dying neurons (Pope and Voigt, 2014) and injured peripheral nerves (Chen et al., 2015) . In addition to phagocytosis of Fig. 4 . Comparison of microarray and multiplex analyses. Protein expression patterns of four upregulated immune markers were examined at 8 and 24 weeks of age in sciatic nerve using multiplex analysis, and compared to gene expression levels generated using microarray. Columns represent the log2 foldchange in gene expression (solid bars) or protein (checkered bars) compared to control mice at the same time point.
L.M. Hinder et al. Experimental Neurology 305 (2018) 33-43 neuronal debris, macrophages are also necessary for the growth of new axons (Niemi et al., 2013) and play a key role in suppressing local inflammation during the repair process via IL-10 production (Shechter et al., 2009) . Combined with our analyses highlighting phagosome-associated pathways, these observations suggest that macrophages are an important component in DPN pathogenesis, though their exact role is unclear. Similarly, neutrophils can serve multiple functions, and their involvement in DPN is supported by our pathway analyses which highlight granulocyte adhesion and diapedesis as a major factor in DPN. Though commonly associated with pro-inflammatory defense against pathogens, neutrophils have been linked to inflammation in obesity (Brotfain et al., 2015) . They are also key cells in initiating the repair response in neuronal tissue (Butterfield et al., 2006; Kurimoto et al., 2013) . Their involvement in DPN may explain the discrepancy we observed between gene expression levels and protein levels: neutrophil granules contain a broad spectrum of cytokines, chemokines, and other immune factors that can be deployed quickly without requiring de novo synthesis (Borregaard et al., 2007) . This aids in the rapid response to pathogens and may explain why we were able to detect increases in specific immune markers with multiplex and not microarray.
The role of innate immune cells such as macrophages and neutrophils in DPN is further reinforced by alterations in pathways associated with toll-like receptor (TLR) signaling. TLRs are used by immune cells to sense the local environment (Akira and Takeda, 2004) and are often upregulated in patients with neuropathy or metabolic syndrome (Zhu et al., 2015; Jialal et al., 2012) . Receptor binding can mediate phagocytosis, and its expression can be induced on monocytes by high glucose levels (Dasu et al., 2008) . Moreover, saturated fatty acids can activate innate immune cells via TLRs (Huang et al., 2012; Lee et al., 2001; Lee et al., 2004) supporting the idea that innate immune cells are being differentially affected in the nervous tissue of db/db mice. However, TLRs are produced by and modulate the activity of a number of cell types, including DRG (Nowicki et al., 2010) and Schwann cells (Cheng et al., 2007; Oliveira et al., 2003; Lee et al., 2006) , so their role in DPN may not be limited entirely to the immune system.
Significant changes in soluble immune markers were also observed in SCN of diabetic mice during multiple stages of DPN. These changes are particularly important, as immune cell activity is strongly influenced by the local cytokine milieu (Davis et al., 2013) . During both early and late time points, we observed increased levels of IL-10 which is consistent with the SOM analysis. IL-10 is typically associated with a protective immune function, but in neuropathy it can also associated with hyperalgesia (Uceyler et al., 2015; Wagner et al., 1998) . Interestingly, we did not see any significant changes in SCN tumor necrosis factor (TNF)-α levels despite previous evidence associating elevated plasma TNF-α with obesity and T2D, and DPN. (Zhu et al., 2015; Duksal et al., 2015; Mu et al., 2017; Hussain et al., 2013; Roman-Pintos et al., 2016) There are several possible reasons for this lack of expression. First, although TNF-α is involved in acute hyperalgesia and painful peripheral neuropathy (Cuellar et al., 2004; Martini and Willison, 2016) , peripheral nerve TNF-α levels do not directly associate with peripheral pain phenotypes across rodent models. Jolivalt et al. reported decreased SCN levels in allodynic, hyperalgesic STZ-rats, (Jolivalt et al., 2009 ) while Saleh et al. reported decreased DRG levels in hypoalgesic STZ-rats. (Saleh et al., 2011) Similarly, TNF-α inhibition for 4 weeks in a prevention paradigm improved DPN phenotypes in a rat model of HFD-STZ neuropathy. (Shi et al., 2013) Second, many previous studies linking TNF-α to DPN were conducted in the streptozotocin-induced rodent (Urabe et al., 2015; Jolivalt et al., 2009; Saleh et al., 2011; Yamakawa et al., 2011) which models autoimmune-driven T1D. Finally, TNF-α can drive neurite outgrowth (Saleh et al., 2011) , and its absence may be a sign of reduced neuronal repair in DPN.
Finally, we also found that MMP-12 was highly elevated in db/db mice. These changes were observed at the gene expression and protein levels and are consistent with our previous observations O'Brien et al., 2015) . We also have preliminary data on MMP12 function, with in situ zymography data indicating an increase in MMP12 activity in the diabetic nerve environment (data not shown). MMP-12 can play multiple roles -both positive and negative -in neuronal tissue depending on the context (Agrawal et al., 2008) . It has been shown to regulate both insulin sensitivity and inducible nitric oxide synthase (iNOS) (Lee et al., 2014) -an immune-mediated source of ROS -and can exacerbate existing tissue damage (Wells et al., 2005) . The involvement of ROS would be consistent with our RNA data as well as previous studies (Hur et al., 2010; Sandireddy et al., 2014) . However, the absence of MMP-12 also delays myelin formation (Larsen et al., 2006) and can exacerbate damage to the nervous system in mouse models of multiple sclerosis (Goncalves DaSilva and Yong, 2009 ). Thus, whether MMP-12 is playing a protective or destructive role in DPN is unclear. One hypothesis is that diabetes causes upregulation of plasminogen activator inhibitor-1 and MMPs, resulting in extracellular matrix remodeling and basement membrane thickening, leading to fibrosis and nerve dysfunction. Further investigation is needed to fully understand the role of MMP12 in DPN.
Together, our data point to the immune system as a major factor in DPN, with innate immune cells likely playing a central role. Multiple forms of analysis -SOM, DEG, and multiplex -all detected upregulated markers of immunity in DPN, and this involvement is consistent during all stages of disease. Interestingly, we observed that the local neuronal immune environment does not necessarily reflect previously reported global immune changes in diabetes. The exact role of the immune response in DPN therefore requires future study. However, the continued involvement of the immune system during all stages of DPN suggests that immune modification may be a viable therapeutic strategy.
